A Bird's Eye View of Non Alcoholic Fatty Liver Disease - an Insulin Resistant State
DOI:
https://doi.org/10.5457/ams.v39i1.153Keywords:
Steatosis, steatohepatitis, Nonalcoholic fatty liver disease(NAFLD), Non alcoholic steatohepatitis (NASH), Insulin resistance, Type 2 Diabetes MellitusAbstract
Nonalcoholic fatty liver disease (NAFLD) is an increasingly recognized form of chronic liver disease. It encompasses a spectrum of conditions associated with lipid deposition in hepatocytes. It ranges from steatosis (simple fatty liver), to nonalcoholic steatohepatitis (NASH—fatty changes with inflammation and hepatocellular injury or fibrosis), to advanced fibrosis and cirrhosis. Studies have suggested that although simple fatty liver is a benign condition, NASH may progress to fibrosis and lead to end-stage liver disease. The disease is mostly silent and often discovered through incidentally elevated liver enzyme levels. It is strongly associated with obesity and insulin resistance and is currently considered by many as the hepatic component of the metabolic syndrome. NASH cirrhosis is now one of the leading indications for liver transplantation particularly in the United States. As NAFLD is considered to be one of the insulin resistant states like Type 2 Diabetes Mellitus (T2M) a brief understanding of the disease is essential in regions where obesity and T2M are prevalent in the majority of the population. Therefore the present review outlines the salient features of NAFLD.
Downloads
Published
Issue
Section
License
Copyright transfer
The listed authors warrant that they are the authors and sole owners of the submitted manuscript. The authors also warrant that the work is original; that it has not been previously published in print or electronic format and is not under consideration by another publisher or electronic medium; that it has not been previously transferred, assigned, or otherwise encumbered; and that the authors have full power to grant such rights. With respect to the results of this work, the manuscript of this or substantially similar content will not be submitted to any other journal until the review process in the Acta Medica Salinianana has been officially completed (acceptance or rejection of the manuscript). The paper will not be withdrawn from the review process by the Acta Medica Saliniana Editorial Board until the review process is completed. The authors will comply with the requests of the Acta Medica Saliniana Editors and reviewers to improve the paper for publication. The eventual disagreements will be submitted in a written form; the authors are aware that the disagreement(s) with the Acta Medica Saliniana requests may result in the rejection of the manuscript. The authors hereby grant to the Acta Medica Saliniana the right to edit, revise, abridge, and condense the manuscript. If the manuscript is accepted for publication in the Acta Medica Saliniana, the authors hereby transfer the copyright of the paper to the Acta Medica Saliniana. The authors permit the Acta Medica Saliniana to allow third parties to copy any part of the journal without asking for permission, provided that the reference to the source is given. For papers with more than one author: All other co-authors agree to allow the corresponding author to make decisions regarding prepublication release of the information in the paper to the media, federal agencies, or both.
